A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia

Leuk Lymphoma. 2022 May;63(5):1261-1264. doi: 10.1080/10428194.2021.2022141. Epub 2021 Dec 31.

Authors

Andrea Messori¹, Melania Rivano², Daniele Mengato³, Luca Cancanelli⁴, Lorenzo Di Spazio⁵, Marco Chiumente⁶

Affiliations

¹ HTA Unit, Regional Health Service, Firenze, Italy.
² Clinical Oncology Pharmacy Department, A. Businco Hospital, Cagliari, Italy.
³ Hospital Pharmacy Department, Azienda Ulss Padova, Padova, Italy.
⁴ Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Treviso, Italy.
⁵ Hospital Pharmacy Department, S. Chiara Hospital, Trento, Italy.
⁶ Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milan, Italy.

PMID: 34969325
DOI: 10.1080/10428194.2021.2022141

No abstract available

Publication types

Letter

MeSH terms

Adult
Antigens, CD19
Cost-Benefit Analysis
Humans
Immunotherapy, Adoptive
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*

Substances

Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen